1
|
Left ventricular volumes on positron emission tomography: validation against cardiovascular magnetic resonance. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.306] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Introduction
Cardiovascular magnetic resonance (CMR) is the gold standard for determination of left ventricular volumes (LVV), including end diastolic volume (LVEDV) and end systolic volume (LVESV). With incorporation of ECG gating, the quantitative analysis of ventricular function can be achieved in Positron Emission Tomography (PET) studies. However, the accuracy of LVV quantification using PET has not been shown in previous studies.
Purpose
We aimed to assess the inter-study variability of LVEDV and LVESV between CMR and PET.
Methods
Consecutive patients who underwent both PET and CMR within 1 year were identified from prospective institutional registries. LVV on PET was compared against CMR as a reference standard using several statistical measures of agreement.
Results
The study population consisted of 233 patients (mean age 60.8±13.6 years, 64.8% male). The median (IQR) duration between CMR and PET was 41 (11–96) days. The median (IQR) LVEDV values were 144 (107–196) on PET and 178 (138–236) on CMR (mean difference 36.09±2.36, p<0.001). As shown in Figure 1, there was a good correlation (Spearman rho=0.88, p<0.001; Intraclass Correlation Coefficient 0.88, 95% CI 0.84–0.90, P<0.001) with moderate limits of agreement (95% limits of agreement −108.17–35.99). A total of 0% and 3.9% of the cohort had LVEDV >150 ml/m2 by CMR and PET respectively. Overall results were similar with LVESV values and similar in subgroup analysis of patients with a low EF (<40%), a coronary artery disease scar, LV hypertrophy and of patients with defibrillators.
Conclusion
Our analysis has shown a good correlation of LVV between PET and CMR, indicating PET derived LVV can accurately be used in the diagnosis and management of patients.
Funding Acknowledgement
Type of funding sources: None.
Collapse
|
2
|
Coronary microvascular health in patients with prior COVID-19 infection and no known CAD. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.310] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Introduction
Although most patients recovering from acute COVID-19 infection have complete resolution of symptoms, some have cardiopulmonary symptoms lingering long after the acute phase of the disease. One proposed mechanism involves chronicity of COVID-19 associated with myocarditis and endotheliopathy.
Purpose
To determine the coronary microvascular health of patients with prior COVID-19 and no known coronary artery disease (CAD) using positron emission tomography (PET).
Methods
Cases consisting of patients without known CAD but previous COVID-19 infection who had clinically indicated PET imaging were matched 1:4 on clinical and cardiovascular risk factors to controls having no prior COVID-19 infection. Myocardial blood flow (MBF) in ml/gm/min was obtained from dynamic images at rest and peak hyperemia. The coronary flow reserve (CFR) was calculated as the ratio of stress to rest MBF of the left ventricle. Coronary microvascular dysfunction (CMD) was defined as CFR<2.
Results
The study population consisted of 315 patients, 25% (n=80) of which had prior COVID-19 infection (mean±SD age 64±11 years, 46% men). The median (IQR) number of days between COVID-19 infection and PET imaging was 190 (85–268) days. After adjusting for age, gender and cardiovascular risk factors, patients with prior COVID-19 and no known CAD had a statistically significant higher odds of having a CFR <2 (OR 4.9, 95% CI 2.3–10.1 p<0.001) and CFR <2 normalized to patient's rate-systolic blood pressure product (OR 2.8, 95% CI 1.6–5.0 p=0.001). The annualized event rate for the composite outcome of all-cause death, myocardial infarction, admission for heart failure exacerbation and late revascularization was higher in cases vs controls and in those with CMD.
Conclusion
Our analysis showed that patients with prior COVID-19 and no known CAD had higher rates of CMD, and that the presence of CMD was associated with higher risk of incident cardiovascular events.
Funding Acknowledgement
Type of funding sources: None.
Collapse
|